Literature DB >> 16457925

Rethinking John Snow's South London study: a Bayesian evaluation and recalculation.

Thomas Koch1, Kenneth Denike.   

Abstract

Famously, John Snow attempted to convince a critical professional audience that public water supplied to South London residents by private companies was a principal vector for the transmission of cholera. The result has been called the sine qua non of the "epidemiological imagination," a landmark study still taught today. In fact, Snow twice attempted to prove public water supplies spread cholera to the South London population. His first, published in 1855, suffered from an incomplete data set that limited its descriptive and predictive import. In 1856, armed with new data, Snow published a more definitive study. This paper describes a previously unacknowledged methodological and conceptual problem in Snow's 1856 argument. We review the context of the South London study, identify the problem and then correct it with an empirical Bayes estimation (EBE) approach. The result hopefully revitalizes Snow's research as a teaching case through the application of a contemporary statistical approach.

Mesh:

Year:  2006        PMID: 16457925     DOI: 10.1016/j.socscimed.2005.12.006

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  3 in total

1.  John Snow, hero of cholera: RIP.

Authors:  Tom Koch
Journal:  CMAJ       Date:  2008-06-17       Impact factor: 8.262

Review 2.  Regulatory decisions on endocrine disrupting chemicals should be based on the principles of endocrinology.

Authors:  Laura N Vandenberg; Theo Colborn; Tyrone B Hayes; Jerrold J Heindel; David R Jacobs; Duk-Hee Lee; John Peterson Myers; Toshi Shioda; Ana M Soto; Frederick S vom Saal; Wade V Welshons; R Thomas Zoeller
Journal:  Reprod Toxicol       Date:  2013-02-11       Impact factor: 3.143

3.  Commentary: nobody loves a critic: Edmund A Parkes and John Snow's cholera.

Authors:  Tom Koch
Journal:  Int J Epidemiol       Date:  2013-12       Impact factor: 7.196

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.